GTB-3550 TRIKE / GT Biopharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GTB-3550 TRIKE / GT Biopharma
NCT03214666: GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Terminated
1/2
12
US
GTB-3550 TriKE® Phase I, CD16/IL-15/CD33, GTB-3550 TriKE® Phase II
GT Biopharma, Inc.
High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Systemic Mastocytosis, Mast Cell Leukemia
08/21
09/21

Download Options